Tonix Pharmaceuticals (TNXP) Competitors $37.39 +1.54 (+4.29%) As of 01:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TNXP vs. IMCR, TVTX, AUPH, CDTX, BHVN, JANX, EWTX, HROW, WVE, and ARDXShould you be buying Tonix Pharmaceuticals stock or one of its competitors? The main competitors of Tonix Pharmaceuticals include Immunocore (IMCR), Travere Therapeutics (TVTX), Aurinia Pharmaceuticals (AUPH), Cidara Therapeutics (CDTX), Biohaven (BHVN), Janux Therapeutics (JANX), Edgewise Therapeutics (EWTX), Harrow (HROW), WAVE Life Sciences (WVE), and Ardelyx (ARDX). These companies are all part of the "pharmaceutical products" industry. Tonix Pharmaceuticals vs. Its Competitors Immunocore Travere Therapeutics Aurinia Pharmaceuticals Cidara Therapeutics Biohaven Janux Therapeutics Edgewise Therapeutics Harrow WAVE Life Sciences Ardelyx Tonix Pharmaceuticals (NASDAQ:TNXP) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership. Do institutionals & insiders have more ownership in TNXP or IMCR? 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 0.0% of Tonix Pharmaceuticals shares are owned by company insiders. Comparatively, 10.4% of Immunocore shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has higher valuation & earnings, TNXP or IMCR? Immunocore has higher revenue and earnings than Tonix Pharmaceuticals. Immunocore is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTonix Pharmaceuticals$10.09M32.59-$130.04M-$39.47-0.95Immunocore$310.20M5.36-$51.09M-$0.40-82.53 Do analysts prefer TNXP or IMCR? Tonix Pharmaceuticals presently has a consensus target price of $70.00, indicating a potential upside of 86.67%. Immunocore has a consensus target price of $58.00, indicating a potential upside of 75.70%. Given Tonix Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Tonix Pharmaceuticals is more favorable than Immunocore.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tonix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Immunocore 1 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more risk and volatility, TNXP or IMCR? Tonix Pharmaceuticals has a beta of 1.7, indicating that its stock price is 70% more volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Does the media prefer TNXP or IMCR? In the previous week, Tonix Pharmaceuticals had 23 more articles in the media than Immunocore. MarketBeat recorded 27 mentions for Tonix Pharmaceuticals and 4 mentions for Immunocore. Immunocore's average media sentiment score of 1.08 beat Tonix Pharmaceuticals' score of 0.46 indicating that Immunocore is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tonix Pharmaceuticals 12 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Neutral Immunocore 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is TNXP or IMCR more profitable? Immunocore has a net margin of -5.70% compared to Tonix Pharmaceuticals' net margin of -828.22%. Immunocore's return on equity of -5.40% beat Tonix Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tonix Pharmaceuticals-828.22% -57.93% -51.04% Immunocore -5.70%-5.40%-1.93% SummaryImmunocore beats Tonix Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Tonix Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TNXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNXP vs. The Competition Export to ExcelMetricTonix PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$328.88M$2.82B$5.82B$9.71BDividend YieldN/A1.66%3.84%4.09%P/E Ratio-0.9522.8430.9025.97Price / Sales32.59764.31469.81120.77Price / CashN/A173.2237.1558.38Price / Book1.965.839.116.37Net Income-$130.04M$31.83M$3.26B$265.56M7 Day Performance-27.09%1.84%1.85%1.71%1 Month Performance-16.20%4.50%4.86%1.05%1 Year Performance13.57%11.24%31.15%20.94% Tonix Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNXPTonix Pharmaceuticals3.1318 of 5 stars$37.39+4.3%$70.00+87.2%-0.4%$327.90M$10.09M-0.9550Gap UpIMCRImmunocore1.8222 of 5 stars$33.28+0.7%$58.00+74.3%-10.6%$1.67B$310.20M-83.18320Positive NewsTVTXTravere Therapeutics2.4131 of 5 stars$18.33+0.5%$32.21+75.8%+104.7%$1.64B$233.18M-9.00460AUPHAurinia Pharmaceuticals2.6607 of 5 stars$12.27+1.5%$12.00-2.2%+83.3%$1.62B$235.13M28.62300Positive NewsCDTXCidara Therapeutics3.5478 of 5 stars$63.17-0.6%$64.14+1.5%+419.2%$1.60B$1.27M-5.6890BHVNBiohaven3.813 of 5 stars$14.91+4.8%$53.75+260.5%-64.6%$1.58BN/A-1.95239Trending NewsAnalyst ForecastOptions VolumeGap UpJANXJanux Therapeutics2.0957 of 5 stars$24.88-0.4%$91.89+269.4%-46.5%$1.49B$10.59M-13.7830EWTXEdgewise Therapeutics2.3289 of 5 stars$13.94+0.1%$41.60+198.4%-30.2%$1.48BN/A-9.0660Analyst ForecastHROWHarrow3.6068 of 5 stars$39.41-1.5%$64.67+64.1%-4.8%$1.47B$199.61M-158.44180Analyst RevisionWVEWAVE Life Sciences4.7738 of 5 stars$9.09+2.0%$20.27+123.0%+66.8%$1.44B$108.30M-10.04240Positive NewsARDXArdelyx4.3143 of 5 stars$5.91+1.2%$11.50+94.6%-4.1%$1.43B$333.61M-25.7190Positive News Related Companies and Tools Related Companies Immunocore Alternatives Travere Therapeutics Alternatives Aurinia Pharmaceuticals Alternatives Cidara Therapeutics Alternatives Biohaven Alternatives Janux Therapeutics Alternatives Edgewise Therapeutics Alternatives Harrow Alternatives WAVE Life Sciences Alternatives Ardelyx Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TNXP) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tonix Pharmaceuticals Holding Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tonix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access